Dishman Carbogen Amcis Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/fa7rcwug7eoh7a9hfwozjf88.pdf

Key Takeaways


CEO Succession & French Milestones

Pascal Villemagne: "It's a bit of a bittersweet moment that I have to address to you today as you may have read in the recent news, I'm going to step down from my CEO role at Carbogen Amcis by the end of this fiscal year on the 31st of March."

Revenue Mix & the Commercial-Development Dynamic

Pascal Villemagne: "If they have a franchise at 100 crore and it goes at 300 crore. Very often, they are not putting all their eggs in the same basket. So, if we start to be sole supplier at the very beginning, when they start to grow, they add over a supplier to secure their supply chain. So, we don't see that growth on our side because they are dividing their volumes with and among other service provider."

Segment-Level Performance

SegmentTrendCommentary
Swiss activities▲ StrongDriven by commercial productions; expected to achieve "a number above digits" by fiscal year-end.
French business▲ InflectingGMP audit passed, second line operational, new customer wins booked; breakeven targeted next year.
India business▬ ImprovingPerformed quite well; next year described as "the real year of turnaround" for India facilities.
Netherlands (vitamin D / cholesterol)▼ Soft, recoveringDifficult start to the year on vitamin D analogues due to aggressive competition; cholesterol orders now moving in the right direction; Q4 expected to be extremely strong on higher calcifediol sales.
ADC / bioconjugation▬ Development-stageOnly development revenue currently; commercial production expected FY26–27 after customers obtain market authorisations.

Balance Sheet, Covenants & Capital Allocation


Margins & Tax

Harshil Dalal: "I think it would still be at about 22, and then it will go to say 24, 25."

Guidance & Commitments

CommitmentSpecificsTimeline
French GMP certificationOfficial certification expectedBy end of current quarter (Q4 FY25)
France breakevenFrench entity to break evenNext financial year (FY26)
Interest cost reductionReduce by ~INR 10 cr in Q4; from INR 48–50 cr range to INR 30 crQ4 FY25; within a couple of quarters
FY25 revenue~INR 2,700 cr plusFY25
FY25 EBITDAIn excess of INR 400 crFY25
FY26 EBITDAExceeding INR 500 crFY26
EBITDA margin trajectory17–18% (FY25) → 20% (FY26) → 22% → 24–25%By FY28
Net leverageReduce to 1.5x–2.0xWithin 3 years
Annual capex$20–25 mn p.a.Next 3 years
Revenue CAGR~10% over a 3–5 year view3–5 year horizon
ADC commercial productionCommercial revenue to begin after customers obtain market authorisationsFY26–27

Key Metrics

MetricQ3 FY25
Revenue₹682 cr, up from ₹505 cr in Q3 FY24 for Carbogen Amcis CRAMS segment
9M revenue₹1,995 cr, compared to ₹1,961 cr in 9M FY24
EBITDA₹140.6 cr, up 230% YoY from ₹42.5 cr in Q3 FY24
Operating margin20.6%, compared to 16% for the 9M period
Profit before tax₹27 cr, down from ₹42 cr in Q2 FY25 due to higher finance costs
Finance cost₹48.78 cr, up 47% YoY from ₹33 cr in Q3 FY24
COGS as % of revenue14%, an outlier quarter; typical consolidated COGS is 17–18%
Carbogen Amcis CRAMS segment margin23.7%, up from 19.9% in Q3 FY24
Vitamin D analogues and cholesterol segment margin14.6%, down from 16.6% in Q3 FY24
India NCE APIs and Intermediates segment margin~11%
Quats and Generics segment margin7.3%
Commercial vs development revenue split60% commercial, 40% development, versus a typical 50-50 full-year split
Net debtCHF 16.8 cr, down CHF 0.5 cr from September 30, 2024
9M capital expenditure$20.8 million
France subsidiary revenue$3 million in the quarter, with a loss of $1.1 million
FY25 revenue guidance~₹2,700 cr+ for the full year
FY25 EBITDA guidance₹425–450 cr for the full year
Revenue CAGR outlook (3–5 years)~10%